COX2 inhibition in the treatment of COVID-19: Review of literature to propose repositioning of celecoxib for randomized controlled studies

COX2 inhibition in the treatment of COVID-19: Review of literature to propose repositioning of celecoxib for randomized controlled studies

Coronavirus-triggered pulmonary and systemic disease, i.e. systemic inflammatory response to virally triggered lung injury, named COVID-19, and ongoing discussions on refining immunomodulation in COVID-19 without COX2 inhibition prompted us to search the related literature to show a potential target...

Full description

Bibliographic Details
Main Authors: Semih Baghaki, Can Ege Yalcin, Hayriye Sema Baghaki, Servet Yekta Aydin, Basak Daghan, Ersin Yavuz
Format: Article
Language:English
Published: Elsevier 2020-12-01
Series:International Journal of Infectious Diseases
Subjects:
COX2
COVID-19
Immunomodulation
Coronavirus
Celecoxib
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971220321822

Internet

http://www.sciencedirect.com/science/article/pii/S1201971220321822

Similar Items